Company
UroGen Pharma Ltd. (URGN)
Standardized SEC financial data for UroGen Pharma Ltd. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001668243 · NASDAQ · Pharmaceutical Preparations.
Gross margin
88.7%
Operating margin
-113.7%
Net margin
-139.8%
Revenue growth (YoY)
21.4%
Return on equity
145.5%
Free cash flow
-$162.7M
Debt / equity
-1.19×
Current ratio
4.01×
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.8M | $48.0M | $64.4M | — | $90.4M | $109.8M |
| Cost of revenue |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $52.9M | $66.9M | $55.4M | $141.5M | $241.7M | $120.5M |
| Inventory |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$105.9M | -$84.9M | -$87.6M | -$76.4M | -$96.8M | -$162.4M |
| Capital expenditures |
Get URGN data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/URGN/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/URGN/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"